Literature DB >> 21910797

Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.

Beth McLellan1, Holly Kerr.   

Abstract

Multikinase inhibitors have become first-line agents for treatment of multiple systemic cancers. These agents are very effective but can also cause a variety of toxicities affecting the skin, hair, and nails. One of the most common reactions is the hand-foot skin reaction, distinct from hand-foot syndrome caused by more traditional chemotherapy agents. All of these cutaneous reactions can negatively affect patients' quality of life and can lead to dose modifications and treatment interruptions. This article reviews the cutaneous toxicities from sorafenib and sunitinib with emphasis on treatment strategies.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910797     DOI: 10.1111/j.1529-8019.2011.01435.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  17 in total

1.  Chemotherapy interruptions in relation to symptom severity in advanced breast cancer.

Authors:  Gwen Wyatt; Alla Sikorskii; Irena Tesnjak; David Victorson; Gordan Srkalovic
Journal:  Support Care Cancer       Date:  2015-03-25       Impact factor: 3.603

2.  The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology.

Authors:  Roger T Anderson; Karen N Keating; Helen A Doll; Fabian Camacho
Journal:  Oncologist       Date:  2015-06-17

3.  Sorafenib-associated facial acneiform eruption.

Authors:  Philip R Cohen
Journal:  Dermatol Ther (Heidelb)       Date:  2014-12-25

4.  Integrating mHealth in Oncology: Experience in the Province of Trento.

Authors:  Enzo Galligioni; Enrico Maria Piras; Michele Galvagni; Claudio Eccher; Silvia Caramatti; Daniela Zanolli; Jonni Santi; Flavio Berloffa; Marco Dianti; Francesca Maines; Mirella Sannicolò; Marco Sandri; Lara Bragantini; Antonella Ferro; Stefano Forti
Journal:  J Med Internet Res       Date:  2015-05-13       Impact factor: 5.428

Review 5.  Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

Authors:  B McLellan; F Ciardiello; M E Lacouture; S Segaert; E Van Cutsem
Journal:  Ann Oncol       Date:  2015-06-01       Impact factor: 32.976

6.  Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.

Authors:  Amrita Sil; Nilay Kanti Das
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

Review 7.  The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis.

Authors:  Chen Peng; Lei Jie-Xin
Journal:  Eur J Hosp Pharm       Date:  2020-09-03

8.  Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition.

Authors:  Kazuhiro Yamamoto; Atsushi Uda; Akira Mukai; Kazuhiko Yamashita; Manabu Kume; Hiroo Makimoto; Toshinori Bito; Chikako Nishigori; Takeshi Hirano; Midori Hirai
Journal:  J Exp Clin Cancer Res       Date:  2013-10-25

Review 9.  Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.

Authors:  Beth Eaby-Sandy; Carolyn Grande; Pamela Hallquist Viale
Journal:  J Adv Pract Oncol       Date:  2012-05

10.  Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3).

Authors:  Kazuhiro Yamamoto; Atsushi Mizumoto; Kohji Nishimura; Atsushi Uda; Akira Mukai; Kazuhiko Yamashita; Manabu Kume; Hiroo Makimoto; Toshinori Bito; Chikako Nishigori; Tsutomu Nakagawa; Takeshi Hirano; Midori Hirai
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.